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Mesenchymal stromal cells (MSC) hold great promise for tissue engineering and
cell-based therapies due to their multilineage differentiation potential and intrinsic
immunomodulatory and trophic activities. Over the past years, increasing evidence has
proposed extracellular vesicles (EVs) as mediators of many of the MSC-associated
therapeutic features. EVs have emerged as mediators of intercellular communication,
being associated with multiple physiological processes, but also in the pathogenesis of
several diseases. EVs are derived from cell membranes, allowing high biocompatibility
to target cells, while their small size makes them ideal candidates to cross biological
barriers. Despite the promising potential of EVs for therapeutic applications, robust
manufacturing processes that would increase the consistency and scalability of EV
production are still lacking. In this work, EVs were produced by MSC isolated
from different human tissue sources [bone marrow (BM), adipose tissue (AT), and
umbilical cord matrix (UCM)]. A serum-/xeno-free microcarrier-based culture system
was implemented in a Vertical-WheelTM bioreactor (VWBR), employing a human platelet
lysate culture supplement (UltraGROTM-PURE), toward the scalable production of MSC-
derived EVs (MSC-EVs). The morphology and structure of the manufactured EVs were
assessed by atomic force microscopy, while EV protein markers were successfully
identified in EVs by Western blot, and EV surface charge was maintained relatively
constant (between −15.5 ± 1.6 mV and −19.4 ± 1.4 mV), as determined by zeta
potential measurements. When compared to traditional culture systems under static
conditions (T-flasks), the VWBR system allowed the production of EVs at higher
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concentration (i.e., EV concentration in the conditioned medium) (5.7-fold increase
overall) and productivity (i.e., amount of EVs generated per cell) (3-fold increase
overall). BM, AT and UCM MSC cultured in the VWBR system yielded an average of
2.8 ± 0.1 × 1011, 3.1 ± 1.3 × 1011, and 4.1 ± 1.7 × 1011 EV particles (n = 3),
respectively, in a 60 mL final volume. This bioreactor system also allowed to obtain
a more robust MSC-EV production, regarding their purity, compared to static culture.
Overall, we demonstrate that this scalable culture system can robustly manufacture
EVs from MSC derived from different tissue sources, toward the development of novel
therapeutic products.
Keywords: extracellular vesicles, mesenchymal stromal cells (MSC), scalable production, bioreactors, serum-
/xenogeneic-free
INTRODUCTION
Mesenchymal stromal cells (MSC) exhibit multilineage
differentiation ability, as well as intrinsic immunomodulatory
and trophic activities, standing as promising candidates for
tissue engineering and cell-based therapies (Caplan and Dennis,
2006; da Silva Meirelles et al., 2009). MSC are able to inhibit
apoptosis and scarring (fibrosis), promote angiogenesis and
support growth and differentiation of progenitor cells into
functional regenerative units (Caplan and Dennis, 2006; da Silva
Meirelles et al., 2009). The array of beneficial effects attributed
to MSC has made them one of the most studied cells in clinical
trials (Heathman et al., 2015). The trophic activity of MSC
relies greatly on the secretion of bioactive factors that assist in
repair and regeneration processes through paracrine signaling
(Caplan and Dennis, 2006; da Silva Meirelles et al., 2009).
Recently, increasing evidence suggests that several MSC-
associated paracrine therapeutic features are mediated by
extracellular vesicles (EVs) (Bruno et al., 2009; Lai et al.,
2010; Lener et al., 2015; Börger et al., 2017). EVs, such
as exosomes and microvesicles, are lipid membrane enclosed
structures actively secreted by cells. These vesicles have emerged
as relevant mediators of intercellular communication, through
the transfer of a cargo of proteins and RNA (i.e., microRNA
and mRNA), which trigger alterations on host cells (Raposo
et al., 1996; Ratajczak et al., 2006; Valadi et al., 2007).
Their small size (generally 50 – 1000 nm) and resemblance
to the cell membrane makes EVs ideal candidates to cross
biological barriers, thus providing high biocompatibility to
target cells (Alvarez-Erviti et al., 2011; El Andaloussi et al., 2013;
Van Niel et al., 2018).
EV can be used in therapeutic settings through two different
approaches. On one hand, EVs are able to mediate some of the
therapeutic effects from their cells of origin (Lai et al., 2010;
Bruno et al., 2012). Therefore, EVs could be potentially used
in substitution of their cell of origin, as a cell-free therapy
triggering equivalent therapeutic effect. On the other hand, EVs
can be used as drug delivery vehicles, by loading EVs with
therapeutic cargo, as an alternative to synthetic drug delivery
systems (Batrakova and Kim, 2015).
MSC are particularly interesting for EV production for a
number of reasons. MSC are considered immune evasive cells
and the safety of their administration has already been confirmed
in a number of clinical trials (Lalu et al., 2012). Therefore, it is
reasonable to assume that MSC-derived EVs (MSC-EVs) are not
prone to immune reaction from the host immune system (Mendt
et al., 2018; Elahi et al., 2020), and promising for the development
of allogeneic (i.e., off-the-shelf) therapeutic products. MSC are
intrinsically therapeutic, with promising applications for multiple
diseases and MSC-EVs convey similar benefits as well (Lener
et al., 2015; Phinney and Pittenger, 2017). Finally, MSC show
great ability for expansion when cultured ex vivo and robust
expansion platforms have already been established (Rafiq et al.,
2013; dos Santos et al., 2014; Schirmaier et al., 2014; Carmelo
et al., 2015; Mizukami et al., 2016; Lawson et al., 2017).
Despite the promising potential of EVs for therapeutic
applications, robust manufacturing processes that would increase
the consistency and scalability of EV production are still lacking.
Similarly to the cell therapy context, where large cell numbers
per dose are required (Ren et al., 2012; Golpanian et al., 2016;
Wysoczynski et al., 2018), very large numbers of EVs are expected
to be required for clinical use (e.g., each patient may require 0.5 –
1.4 × 1011 EVs, Kordelas et al., 2014). In order to achieve such
large production capacities, robust and scalable manufacturing
processes need to be developed.
The development of cell-based therapies faces multiple
challenges (recently reviewed de Almeida Fuzeta et al., 2019)
and these also apply to manufacturing of EV products. One of
these challenges is the use of appropriate cell culture medium.
The most commonly used culture medium supplement in ex vivo
expansion platforms of MSC is fetal bovine serum (FBS), which
presents several disadvantages when considering the production
of cell-based therapies for human use due to their animal origin.
As an alternative to animal derived products, serum-/xenogeneic-
free (S/XF) culture supplements have been developed, such as
human platelet lysates (hPL).
Another major challenge is determining the appropriate
cell culture platform for scalable manufacturing of cell-based
therapies (de Almeida Fuzeta et al., 2019). In order to achieve
large product batches for clinical use, culture platforms require
scalability as well as the ability to monitor and control culture
parameters, which cannot be accomplished in traditional static
culture systems. Multiple bioreactor configurations operating
in dynamic culture conditions have been developed for this
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purpose (de Soure et al., 2016; de Almeida Fuzeta et al., 2019).
Expansion of MSC immobilized on microcarriers has been
explored in stirred-tank bioreactor configurations (de Soure et al.,
2016; de Almeida Fuzeta et al., 2019). These bioreactors use
an agitation system to maintain microcarriers in suspension
and allow medium homogenization. However, agitation impacts
cellular physiology due to increased shear stress.
In order to improve agitation patterns in cell culture, PBS
Biotech has developed scalable Vertical-WheelTM bioreactors
(VWBR) that can provide gentle and uniform mixing with
minimal shear stress. A vertically rotating wheel promotes
radial and axial fluid flow and creates a more homogeneous
hydrodynamic environment compared with traditional stirred-
tank bioreactors. In addition, the Vertical-WheelTM impeller
can fully suspend microcarriers with minimal power input
and thus minimize shear stress effects (Croughan et al., 2016).
Moreover, this technology is scalable, being available at working
volumes that range from 100 mL up to 500 L. Recently, VWBR
have been successfully applied in microcarrier-based cell culture
processes for the expansion of MSC from multiple sources
(Sousa et al., 2015; de Sousa Pinto et al., 2019), as well as for
human induced pluripotent stem cells (Rodrigues et al., 2018;
Nogueira et al., 2019).
In this work, EVs were produced by MSC isolated from
different human tissue sources, namely bone marrow (BM),
adipose tissue (AT), and umbilical cord matrix (UCM). A S/XF
microcarrier-based culture system was implemented in a single-
use VWBR, employing a hPL culture supplement (UltraGROTM-
PURE), toward the production of MSC-EVs.
When compared with traditional static culture systems
(i.e., T-flasks), the bioreactor-based culture system allowed a
substantial improvement in EV production. This culture system
is expected to contribute to robustly manufacture human MSC-
EVs in a scalable manner, which can be applied as intrinsic
medicines or as delivery vehicles in different therapeutic settings.
MATERIALS AND METHODS
MSC Isolation From Human Samples
Human MSC used in this study are part of the cell bank
available at the Stem Cell Engineering Research Group (SCERG),
iBB-Institute for Bioengineering and Biosciences at Instituto
Superior Técnico (IST). MSC were previously isolated/expanded
according to protocols previously established at iBB-IST. UCM
MSC were isolated in hPL-supplemented medium according
to the protocol described by de Soure et al. (2017). BM MSC
were isolated in hPL-supplemented medium by adapting the
protocol for cell isolation using FBS-supplemented medium
described by dos Santos et al. (2010). AT MSC were originally
isolated in FBS-supplemented medium according to Oliveira
et al. (2012), cryopreserved and later adapted for 1 or 2
passages to hPL-supplemented medium. Originally, human
tissue samples were obtained from local hospitals under
collaboration agreements with iBB-IST (bone marrow: Instituto
Português de Oncologia Francisco Gentil, Lisboa; adipose
tissue: Clínica de Todos-os-Santos, Lisboa; umbilical cord:
Hospital São Francisco Xavier, Lisboa, Centro Hospitalar Lisboa
Ocidental, Lisboa). All human samples were obtained from
healthy donors after written informed consent according to
the Directive 2004/23/EC of the European Parliament and
of the Council of 31 March 2004 on setting standards of
quality and safety for the donation, procurement, testing,
processing, preservation, storage and distribution of human
tissues and cells (Portuguese Law 22/2007, June 29), with the
approval of the Ethics Committee of the respective clinical
institution. Human MSC from the different sources (BM,
AT, and UCM) were cryopreserved in a liquid/vapor-phase
nitrogen container.
MSC Expansion in Static Conditions
In general, MSC expansion in static conditions was performed as
previously described (de Sousa Pinto et al., 2019). In summary,
previously isolated BM, AT and UCM MSC were thawed and
plated on T-flasks (Falcon), at a cell density between 3000–6000
cell/cm2. MSC were cultured in low glucose (1 g/L) Dulbecco’s
Modified Eagle’s Medium (DMEM) (Gibco, Life Technologies),
supplemented with 5% v/v of the human platelet lysate (hPL)
UltraGROTM-PURE (AventaCell Biomedical) and Antibiotic-
Antimycotic (1x) (Gibco, Life Technologies).
Cells were maintained at 37◦C and 5% CO2 in a humidified
atmosphere and culture medium was changed every 3–4 days.
At 70–80% cell confluence, MSC were detached from the flasks
using the xeno-free cell detachment solution TrypLETM Select
(1x) (Gibco, Life Technologies) for 7 min at 37◦C. Cell number
and viability were determined using the Trypan Blue (Gibco, Life
Technologies) exclusion method.
After thawing, MSC were passaged at least once before either
final inoculation in T-flasks for EV production under static
conditions or inoculation in VWBR. MSC were always plated at
3000 cell/cm2. For each cell source, MSC from three independent
donors (n = 3) in passages (P) from P4 to P5 were used to
inoculate either the final T-flasks for EV production or the VWBR
[specifically, BM1 (P4); BM2 (P5); BM3 (P4); AT1 (P4); AT2 (P4);
AT3 (P5); UCM1 (P4); UCM2 (P4); UCM3 (P5)] (Figure 1).
MSC-EV Production Under Static
Conditions
For the production of MSC-EVs under static conditions,
previously cultured MSC were passaged to T-175 flasks, at
3000 cells/cm2. Cells were cultured in the same conditions
described before for MSC expansion under static conditions.
When maximum cell confluency in the flasks was achieved
(90–100%), cells were washed once with basal DMEM low
glucose (i.e., supplemented only with Antibiotic-Antimycotic)
and subsequently cultured for 48 h in basal DMEM low glucose
(20 mL per T-175), for medium conditioning. At the end of the
48 h period, the conditioned medium was recovered, centrifuged
(360× g, 10 min) to remove cell debris and stored at 4◦C for less
than 1 week until processing for EV isolation.
After recovery of the conditioned medium, MSC were
detached from the flasks and cell number was determined
as previously described. Cells were re-suspended in
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FIGURE 1 | Workflow of the production and characterization of MSC-EVs in bioreactors and static systems. MSC were isolated from three different human tissue
sources: BM, AT, and UCM. Firstly, MSC were expanded in static conditions (i.e., T-flasks) in hPL supplemented DMEM. These cells were subsequently used to
inoculate a VWBR (5M cells; 100 mL final working volume), as well as to maintain a static culture in T-175 flasks. For each cell source, MSC from three independent
donors (n = 3; BM1, 2, 3; AT1, 2, 3; UCM1, 2, 3) were used to inoculate either the final T-flasks for EV production or the VWBR, in passages from P4 to P5
[specifically, BM1 (P4); BM2 (P5); BM3 (P4); AT1 (P4); AT2 (P4); AT3 (P5); UCM1 (P4); UCM2 (P4); UCM3 (P5)]. Upon reaching stationary growth phase in VWBR or
maximum confluency in static, the culture medium was changed for supplement-free culture medium and culture was maintained for 48 h. Over this period, culture
medium was enriched in EVs secreted by cultured MSC. This conditioned culture medium was recovered and EVs were isolated by precipitation using a
commercially available kit. Finally, EV production was quantified in both static and dynamic systems and samples were characterized using multiple techniques.
MSC, mesenchymal stromal cells; EV, extracellular vesicles; VWBR, Vertical-WheelTM bioreactor; hPL, human platelet lysate; BM, bone marrow; AT, adipose tissue;
UCM, umbilical cord matrix; NTA, nanoparticle tracking analysis; AFM, atomic force microscopy. The cells, T-flask and Eppendorf cartoons were obtained from Smart
Servier Medical Art (https://smart.servier.com).
phosphate-buffered saline (PBS) for pelleting and stored at
−80◦C until further analysis (i.e., Western blots).
MSC Expansion and MSC-EV Production
in the Bioreactor Culture System
Expansion of human MSC in VWBR was generally performed
as previously described (de Sousa Pinto et al., 2019). In
summary, previously isolated and expanded human MSC
were inoculated in a PBS 0.1 MAG bioreactor (PBS Biotech
Inc.) with a working volume of 100 mL. Animal product-
free SoloHill plastic microcarriers (PALL) were used in order
to provide a surface for MSC to adhere and proliferate.
Inoculation in the VWBR was performed in 60 mL of the
same culture medium used for static conditions (i.e., DMEM
low glucose, 5% v/v UltraGROTM-PURE, Antibiotic-Antimycotic
1x), with an initial MSC number of 5 × 106 and 2 g of
microcarriers. The VWBR was placed at 37◦C and 5% CO2 in
a humidified atmosphere.
After an initial intermittent agitation regime, a continuous
agitation mode was set at 25 rpm, as previously described
(de Sousa Pinto et al., 2019). This agitation rate was always
maintained, except for AT MSC culture, which required an
increment in the agitation rate to 30 rpm at day 2 or 3 of culture
and to 35 rpm at day 4 or 5, due to increased medium viscosity
and the subsequent formation of cell aggregates.
After 2 days of culture, 40 mL of fresh culture medium with
a glucose pulse (3 g/L) was added to the VWBR, achieving
a final working volume of 100 mL. From this day onward,
25% v/v of culture medium was exchanged every 24 h, with
the addition of fresh culture medium supplemented with a
glucose pulse (3 g/L). Cell growth and viability were assessed
every day, as previously described (de Soure et al., 2017).
Growth rate was determined by performing an exponential
fitting to experimental data corresponding to the exponential
growth phase. Cell visualization on microcarriers was performed
by staining the cells with 4′,6-diamidino-2- phenylindole
(DAPI, Sigma, 1.5 µg/mL in PBS), as previously described
(de Soure et al., 2017).
When MSC cultures reached stationary growth and the
maximum cell concentration was achieved, the MSC expansion
stage of the process was concluded and the EV production stage
started. The culture medium was removed from the VWBR, after
a 10 min sedimentation of cells attached to microcarriers inside
the vessel. The VWBR was washed with 60 mL basal DMEM
low glucose medium, at 30 rpm agitation, in order to remove
hPL components. The cells on microcarriers were sedimented
once again for 10 min and the washing medium was removed.
MSC were kept in culture in the VWBR for 48 h in 60 mL
basal DMEM low glucose medium, in the same conditions (i.e.,
agitation speed, temperature, O2 and CO2 concentrations) used
for MSC expansion.
At the end of the 48 h period, the whole culture volume
was recovered from the VWBR and transferred to 50 mL
tubes (Falcon), where cells on microcarriers were sedimented
for 10 min. The MSC conditioned medium was recovered
and centrifuged at 360 × g for 10 min, to remove remaining
microcarriers, cells and cell debris. Conditioned medium was
stored at 4◦C for less than 1 week until processing for EV
isolation. After recovery of the conditioned medium, cells
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attached to microcarriers were re-suspended in PBS and stored
at−80◦C for further analysis (i.e., Western blots).
Isolation of EVs From MSC Cultures
EV were isolated using the Total Exosome Isolation reagent
(Invitrogen, Life Technologies), according to the manufacturer
instructions. Briefly, MSC conditioned medium was centrifuged
for 30 min at 2000 × g, to remove cell debris and incubated
overnight at 4◦C with the isolation reagent. This mixture was
then centrifuged for 1 h at 10000 × g and 4◦C. The supernatant
was discarded and the EV fraction was recovered by thoroughly
washing the walls of the centrifuge tube with PBS 1x (Invitrogen,
Life Technologies) in UltraPureTM DNase/RNase-Free Distilled
Water (Invitrogen, Life Technologies). EV samples were re-
suspended in a PBS volume corresponding to a concentration
factor of 20x to 70x relatively to the processed conditioned
medium volume. EV samples were frozen at −80◦C in aliquots




Total protein was quantified in EV samples using the PierceTM
BCA Protein Assay Kit (Thermo Scientific), according to
manufacturer instructions for the microplate procedure. Samples
were quantified either undiluted or after a 2x dilution.
Three replicates were quantified for each sample. Sample
concentration was determined by applying a linear fit to the
bovine serum albumin (BSA) standards and using the resulting
equation to determine each sample concentration from its
absorbance measurement.
Nanoparticle Tracking Analysis
EV size distribution profiles and concentration measurements
were obtained by nanoparticle tracking analysis (NTA), using
a NanoSight LM14c instrument equipped with a 405 nm laser
(Malvern) and NTA software version 3.1 (Malvern). Silica 100 nm
microspheres (Polysciences, Inc.) were routinely analyzed to
check instrument performance (Gardiner et al., 2013). NTA
acquisition and post-acquisition settings were optimized and
kept constant for all samples. These settings were established
using silica 100 nm microspheres (Gardiner et al., 2013) and
subsequently adjusted for optimal detection of MSC-EVs.
EV samples were diluted in 2 mL of PBS 1x in UltraPureTM
DNase/RNase-Free Distilled Water, to obtain a final
concentration in the range of 5 × 108 to 3 × 109 particles/mL.
Samples were measured using a camera level of 13. Acquisition
temperature was controlled and maintained at 20◦C. Each
sample was recorded 10 times for 30 s, using fresh sample for
each acquisition (by pushing the sample syringe). The detection
chamber was thoroughly washed with PBS between each sample
measurement. A threshold level of 7 was applied for video
processing. Each video recording was analyzed to obtain the size
and concentration of EVs.
Western Blot
Cells were lysed with Catenin lysis buffer (1% Triton X-100,
Sigma, 1% Nonidet P-40, Sigma, in PBS) supplemented with
protease inhibitor (Sigma) and phosphatase inhibitor (Sigma) for
10 min on ice and then centrifuged at 14000 × g for 10 min at
4◦C to remove insoluble material. Supernatants were recovered
and used as whole cell lysates (WCL). For CD63 and CD81
detection, cells and EV samples were lysed with RIPA lysis buffer
(150 mM NaCl, 25 mM Tris pH 7.4, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS) and sonicated (three rounds
of 5 s, at 50% intensity). Total protein content in WCL and EV
samples was quantified using the BCA kit as previously described.
Both WCL and EV samples were mixed with sample buffer in
reducing conditions and heated to 100◦C for 10 min. For CD63
and CD81 detection, urea containing sample buffer was used. All
samples were loaded (6–30 µg of total protein) in 4–12% Bis–
Tris polyacrylamide gels (Invitrogen, Life Technologies), in equal
protein content for each gel, and subjected to electrophoresis.
Proteins were transferred into nitrocellulose membranes
using a Power Blotter System (Invitrogen, Life Technologies).
Membranes were blocked with 5% w/v non-fat dry milk solution
in tris-buffered saline (TBS) Tween 20 buffer 1x (Thermo Fisher
Scientific), for 1 h with mild orbital agitation at room temperature
and incubated with primary antibodies overnight at 4◦C. For
CD63 and CD81 detection, membranes were blocked with 5%
BSA solution in TBS Tween 20 buffer 1x. Finally, membranes
were incubated with HRP conjugated secondary antibodies
for 1 h at room temperature and PierceTM ECL Western
Blotting Substrate (Thermo Fisher Scientific) was applied for
membrane revelation.
Primary antibodies included anti-Calnexin (1:1000, BD),
anti-Synthenin (1:1000, Abcam), anti-CD63 (1:1000, Genetex),
anti-CD81 (1:500, Abcam) and anti-GAPDH (1:1000, Santa
Cruz). Secondary antibodies included Goat anti-Mouse IgG
(H + L) Cross-Adsorbed Secondary Antibody, HRP (1:5000,
Invitrogen, Life Technologies) and Goat anti-Rabbit IgG HRP-
conjugated (1:1000, R&D Systems). Image acquisition was
performed on iBrightTM CL1500 Imaging System (Invitrogen,
Life Technologies).
Atomic Force Microscopy Imaging
EV samples were prepared for atomic force microscopy (AFM)
imaging in freshly cleaved mica without any previous dilution.
A volume ranging between 30–70 µL was used and samples
were allowed to deposit during 30 min to 2 h. After this period,
the samples were washed with filtered MilliQ water and air
dried. AFM imaging was performed with a JPK Nano Wizard
IV mounted on a Zeiss Axiovert 200 inverted microscope (Carl
Zeiss). The AFM head is equipped with a 15 µm z-range
linearized piezoelectric scanner and an infrared laser. Uncoated
silicon ACL cantilevers from AppNano were used, with resonance
frequencies and spring constants ranging between 160–225 kHz
and 36–90 N/m, respectively. Scan speeds were between 0.1 and
0.3 Hz. Total areas with 10 × 10 µm were scanned with a
512× 512 pixel resolution, in AC mode. Height and error images
were recorded, and line fitted. Image processing was performed
on JPK SPM data processing software version spm-6.0.55.
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Zeta Potential
EV samples were diluted to a final protein concentration of
25 µg/mL, in PBS. Samples were loaded into disposable zeta
cells with gold electrodes and allowed to equilibrate for 15 min
at 37◦C. Zeta potential measurements consisted in a set of 15
runs, each one resulting from an automatically defined number
of subruns (ranging from 10 to 100) performed on the Zetasizer
Nano ZS (Malvern), at a constant voltage of 40 V.
Lactate Dehydrogenase Activity
Measurements
Cell culture medium samples from VWBR cultures were
recovered daily and centrifuged at 360 × g for 10 min, to
remove remaining microcarriers, cells and cell debris. Lactate
dehydrogenase (LDH) activity was quantified in cell culture
supernatants using the Pierce LDH Cytotoxicity Assay Kit
(Thermo Scientific) by adapting the manufacturer instructions
for the microplate procedure. The same procedure was applied
to a positive control (1 µL LDH Positive Control in 10 mL of 10%
BSA in PBS). Three replicates were quantified for each sample.
The LDH activity was reported as the quotient between the LDH
activity of each sample and the LDH activity of the positive






Statistical analysis was performed using GraphPad Prism 8
Software. Results are presented as mean ± standard error of the
mean (SEM) of the values obtained from different MSC donors
(i.e., biological replicates) or as mean ± standard deviation (SD)
of the values from technical replicates. Paired t-test was applied
to evaluate the statistical significance of the differences in EV
concentration and specific EV concentration in the conditioned
medium from MSC cultures in static and VWBR systems. These
data sets passed normality tests. P-values result from two-
tailed tests with a 95% confidence interval. Differences were
considered significant at P < 0.05 and statistical output was
represented as ∗∗ < 0.01.
RESULTS
MSC Expansion and Medium
Conditioning for MSC-EV Production
From Three Different Human Sources
(BM, AT and UCM) Was Achieved in the
Bioreactor Culture System
Bioreactors have been implemented as scalable platforms for
MSC manufacturing. Building on previous work from our
group (de Sousa Pinto et al., 2019), a S/XF microcarrier-based
culture system implemented in a VWBR originally targeting MSC
expansion was adapted to the production of cell-derived products
such as MSC-EVs and compared with traditional static culture
systems (i.e., T-flasks) (Figure 1).
BM, AT and UCM MSC were successfully expanded in
the VWBR system (Figure 2A, upper panel). The expansion
of BM MSC was the most heterogeneous among donors
(n = 3), with final post-expansion cell numbers ranging between
12.0± 3.6× 106 and 53.4± 5.5× 106, depending on BM donor.
The expansion culture period also ranged from 7 to 11 days in
BM MSC cultures. AT and UCM MSC expansion curves were
more homogeneous, reaching an average of 29.2± 1.7× 106 and
19.9 ± 2.4 × 106 cells, respectively, at the end of the expansion
period. This expansion period was 7 days for AT MSC and
9–10 days for UCM MSC.
Estimated adhesion efficiency of MSC to microcarriers after
VWBR inoculation was higher for AT MSC (110 ± 12%),
followed by BM MSC (68 ± 17%) and UCM MSC (55 ± 4%)
(Table 1). AT MSC adhered and started proliferating in less
than 24 h, which resulted in estimated adhesion efficiencies
higher than 100%. BM MSC showed the highest average growth
rate (0.47 ± 0.05 day−1), which was very similar to AT MSC
(0.45± 0.06 day−1), while UCM MSC showed the lowest growth
rate (0.35 ± 0.09 day−1), as a consequence of the lower initial
adhesion efficiency observed.
In general, BM and AT MSC maintained cell viability close to
100% throughout culture (Figure 2A, lower panel). Cell viability
suffered more oscillations in UCM MSC cultures, especially in the
first days of culture.
Throughout the culture period, microcarrier colonization by
cells increased progressively as MSC expanded (Figure 2B). The
increasing microcarrier occupancy was followed by microcarrier
aggregation, as MSC expansion reached higher cell numbers. We
observed that cell expansion stopped when large microcarrier
aggregates were formed, likely due to lack of surface available to
attach and proliferate (Figures 2A,B).
In some cultures, a significant decrease in cell number
was observed at the start of the medium conditioning stage,
immediately after the culture medium was changed from hPL-
supplemented medium to supplement-free culture medium. This
can be explained, at least partially, by a possible removal of
microcarriers during medium change operation, resulting in a
loss of cells from the vessel. Additionally, it should be noticed
that microcarrier aggregation might affect our estimation of cell
numbers at this stage. In the medium conditioning stage, MSC
were cultured for 48 h in a supplement-free medium, which could
be a stress factor for cell culture. Although a decrease in the
cell number was occasionally observed during the 48 h medium
conditioning period, this was an exception rather than the rule
(Figure 2A). High cell viabilities were maintained (Figure 2A)
and there were no visible differences in microcarrier occupancy
during this stage (Figure 2B). Still, in order to thoroughly assess
if MSC were experiencing induced cell stress, the levels of LDH
activity in culture were monitored during the 48 h conditioning
period. LDH activity can be used as a readout of cell stress, as
this toxic compound is released to cell culture medium upon
plasma membrane damage (Racher et al., 1990). LDH activity
did not change significantly over this period for any of the MSC
sources (Figure 2C). Therefore, there were no indications that
MSC were experiencing significant stress in stirred culture due
to the absence of hPL in the 48 h conditioning period.
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FIGURE 2 | MSC culture in the microcarrier-based bioreactor system. (A) Evolution of cell number (upper panel) and cell viability (lower panel) over culture period
time, for MSC from three different human tissue sources (bone marrow, adipose tissue, and umbilical cord matrix). MSC from three different donors (i.e., three
biological replicates) were used per tissue source, which are represented in three different shades of gray. Two data points are presented for the same day when the
medium conditioning stage (i.e., EV production) started. Results are presented as mean ± SD of cell count for each time point. (B) Representative images of
microcarrier occupation by MSC throughout culture. Cell nuclei were stained with DAPI and images were acquired using a fluorescence microscope. In this case, EV
production started on day 9 of culture and finished on day 11. Scale bar = 100 µm. (C) LDH activity profile during the medium conditioning (i.e., EV production)
stage in the VWBR system. Culture medium samples were taken at 0, 24, and 48 h after medium conditioning started. Results from one experiment for each MSC
source (BM, AT, and UCM). Results are presented as mean ± SD (n = 3). LDH, lactate dehydrogenase; VWBR, Vertical-WheelTM bioreactor; BM, bone marrow; AT,
adipose tissue; UCM, umbilical cord matrix.
Characterization of MSC-EVs Reveals
Improved Properties Upon Bioreactor
Manufacturing
EV were successfully isolated from the conditioned medium of
MSC cultures. We were able to identify the presence of EVs
from static and bioreactor cultures of MSC, from the 3 different
sources (i.e., BM, AT and UCM) through AFM (Figure 3A
and Supplementary Figure 1). Individual vesicles of different
sizes were observed, as well as vesicle aggregates. The formation
of aggregates and collapsed vesicles may be caused by sample
processing techniques, which involve sample dehydration. Larger
vesicles were observed for AT MSC (Figure 3A). These vesicles
may have a higher tendency to aggregate or even fuse together
due to the higher medium viscosity observed in AT MSC cultures.
The production of EVs was also confirmed by Western blot
analysis (Figure 3B and Supplementary Figure 2). The EV
protein markers synthenin, CD63 and CD81 were successfully
detected in EV samples, while the negative EV protein marker
calnexin (a protein from the endoplasmic reticulum) was present
in cells, but absent in EV samples, as expected (Figure 3Bi).
In general, synthenin and CD63 presence were verified for
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TABLE 1 | Parameters from cultures of MSC from three different human sources
(BM, AT, and UCM) in bioreactors.
Adhesion efficiency Growth rate (day−1) Duplication time (day)
BM 68 ± 17% 0.47 ± 0.05 1.49 ± 0.13
AT 110 ± 12% 0.45 ± 0.06 1.60 ± 0.19
UCM 55 ± 4% 0.35 ± 0.09 2.30 ± 0.61
Average initial cell adhesion efficiency, growth rate and duplication time for each
MSC source. Adhesion efficiency was estimated by dividing the total cell number
24 h after inoculation (day 1) by the cell number used in bioreactor inoculation (day
0). Three biological replicates (i.e., MSC from three different human donors) were
used for each MSC source (n = 3). Results are presented as mean ± SEM.
MSC-EVs obtained from both static and bioreactor systems,
using MSC from the 3 different tissue sources (Figure 3Bii).
Interestingly, both synthenin and CD63 presence were increased
when EVs were obtained from bioreactors. Contrarily to EVs,
cells showed higher synthenin expression under static conditions
compared to the bioreactor. CD81 was detected in EVs obtained
from BM and AT MSC obtained from both static and bioreactor
systems, but not from UCM MSC. CD81 was detected in higher
quantity in EVs obtained from AT MSC cultured in bioreactors,
compared with static conditions.
The surface charge of MSC-EVs was also quantified. MSC-
EVs presented a negative surface charge, as determined through
zeta potential measurements (Figure 3C). Overall, no significant
differences were observed in the zeta potential between samples
obtained from static or bioreactor platforms, neither between
different MSC tissue sources. The zeta potentials ranged between
−15.5± 1.6 mV and – 19.4± 1.4 mV.
The size distribution of MSC-EVs was determined by NTA.
In general, MSC-EV samples showed a size distribution profile
mostly enriched in small EVs (<200 nm) (Figures 4A,B).
Although EVs derived from AT MSC showed a more
homogeneous size distribution when obtained from the
bioreactor compared to static cultures, no significant difference
was observed for other MSC sources. The sizes of EVs produced
from AT MSC in the static platform were significantly larger,
possibly due to vesicle aggregation or fusion. Therefore, the
bioreactor system reveals potential to produce EVs with lower
size dispersity, as observed for AT MSC-EVs.
Bioreactor Culture Improves the
Production of MSC-EVs
MSC-EVs produced in the bioreactor system were quantified
by NTA after EV isolation and compared with MSC-EVs
obtained from static cultures. When EVs were produced in the
bioreactor system, their concentration was significantly increased
(Figure 5A), at an overall fold increase of 5.7 ± 0.9 (Table 2).
When analyzed individually, we observed a fold increase of
4.0 ± 0.6 for BM MSC, 4.4 ± 1.2 for AT MSC and 8.8 ± 3.8
for UCM MSC, when EVs were produced in the bioreactor
system (Table 2). Bioreactor cultured UCM MSC yielded the
highest average EV concentration in the conditioned medium
(6.9 ± 1.7 × 109 particles/mL) (Figure 5A). The average EV
concentration in bioreactor cultures was similar for BM and
AT MSC (4.6 ± 0.2 × 109 and 5.1 ± 2.1 × 109 particles/mL,
respectively), although the latter presented higher heterogeneity
between experiments.
In order to evaluate if the conditions in the bioreactor
might modulate the intrinsic capacity of cultured MSC for the
production of EVs compared to static conditions, we estimated
the EV productivity (i.e., specific EV concentration, per cell)
by dividing the concentration of EVs (from NTA) by the cell
concentration at the beginning of the conditioning period. When
EVs were produced in the bioreactor system, EV productivity
increased compared with static culture (Figure 5B) at an overall
fold increase of 3.0 ± 0.5 (Table 2). Although this difference
was not statistically significant (which is likely due to the
heterogeneities between the different tissue sources and donors
used), the bioreactor system allowed an improved productivity of
MSC-EVs for most of the MSC donors used (i.e., in six out of
eight MSC donors).
EV productivity increased in the bioreactor by a fold increase
of 1.4 ± 0.3 for BM MSC, 3.7 ± 1.0 for AT MSC and 3.9 ± 1.4
for UCM MSC (Table 2), compared with static conditions.
Bioreactor cultured UCM MSC yielded the highest average EV
productivity (2.7 ± 0.6 × 104 particles/cell) (Figure 5B). The
average EV productivity in bioreactor cultures was similar for
BM and AT MSC (1.6 ± 0.5 × 104 and 1.7 ± 0.6 × 104
particles/cell, respectively).
A particle to protein ratio (PPR) was also determined by
dividing the EV concentration (determined by NTA) by the total
protein concentration in the same sample (determined through
BCA protein assay). The PPR can be used to assess the purity
of an EV sample, as the higher is this ratio, the lower is the
amount of co-isolated protein contaminants, thus the higher is
the sample purity (Webber and Clayton, 2013). EV samples from
BM and UCM MSC cultures presented a more homogeneous PPR
in the bioreactor system than in static conditions (Figure 5C).
EV samples from AT MSC cultures presented a homogeneous
PPR for both culture platforms, but the average PPR was
slightly higher in the bioreactor. Overall, the PPR was relatively
constant in the bioreactor system, ranging between 1.63 × 108
and 3.40 × 108 particles/µg protein (Figure 5C). PPR was
much more heterogeneous in static conditions (i.e., T-flasks),
ranging between 3.47× 107 and 9.88× 108 particles/µg protein.
Additionally, the median PPR was higher for the EVs produced
in the bioreactor system.
DISCUSSION
MSC hold great promise for the development of cell-based
therapies for a variety of disorders. MSC-derived products such
as MSC-EVs offer the opportunity to develop new therapeutic
products benefiting from MSC regenerative properties in cell-free
formulations. These cell-free therapies are expected to present
significant advantages, obviating the complexity and safety issues
in utilizing cells themselves as therapeutic systems in a clinical
context (Batrakova and Kim, 2015; Conlan et al., 2017).
MSC-EVs can be used as intrinsically therapeutic products,
by mediating some of the effects conveyed by MSC. MSC-EVs
present therapeutic properties for neurological, cardiovascular,
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FIGURE 3 | Characterization of MSC-EVs. (A) Representative AFM images of MSC-EVs obtained in the VWBR system, using MSC from three different human tissue
sources (bone marrow, adipose tissue, and umbilical cord matrix). AFM height images (top) and respective 3D projections (bottom), capturing a total area of 10 × 10
µm. A close-up image focusing on a single EV is presented for each AFM height image. (B) Western blots of MSC lysates and MSC-EV samples. (i) Representative
Western blot images of synthenin, CD63, CD81 and calnexin detection in MSC-EVs and corresponding WCL (i.e., cells) obtained from VWBR cultures. (ii) Western
blot detection of synthenin, CD63 and CD81 in MSC-EV samples and corresponding WCL (i.e., cells), obtained from BM, AT and UCM MSC after EV production in
static and VWBR systems. Detection of the housekeeping protein GAPDH in the same WCL preparations. (C) Zeta potential measurements of the surface charge of
MSC-EVs (mV), obtained in either static or VWBR systems, using MSC from three different human sources (BM, AT, and UCM). Results correspond to one
representative experiment for each condition. Results are presented as mean ± SD. AFM, atomic force microscopy; WCL, whole cell lysates; BM, bone marrow; AT,
adipose tissue; UCM, umbilical cord matrix; VWBR, Vertical-WheelTM bioreactor.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 November 2020 | Volume 8 | Article 553444
fcell-08-553444 October 28, 2020 Time: 18:7 # 10
de Almeida Fuzeta et al. MSC-Derived EV Production in Bioreactors
FIGURE 4 | Size distribution of MSC-EVs. (A) Representative size distribution curves of EV samples obtained from BM, AT, and UCM MSC, cultured in static or
Vertical-WheelTM bioreactor systems. (B) Box plots representing the size distribution profiles of EV samples obtained from BM, AT, and UCM MSC, cultured in static
or Vertical-WheelTM bioreactor systems. The minimum, 1st quartile, median, 3rd quartile and maximum values are represented for each condition. MSC from three
different donors were used for each tissue source (i.e., n = 3 biological replicates). BM, bone marrow; AT, adipose tissue; UCM, umbilical cord matrix.
immunological, kidney and liver diseases, among others (Phinney
and Pittenger, 2017; Keshtkar et al., 2018; Elahi et al.,
2020). MSC-EVs have been described to reduce myocardial
ischemia/reperfusion injury in mice (Lai et al., 2010) and also
allowed improved recovery from acute kidney injury (Bruno
et al., 2012) and from stroke (Doeppner et al., 2015). Indeed,
there are multiple studies describing their pro-angiogenic (Bian
et al., 2014; Vrijsen et al., 2016) and wound healing capacity
(Zhang et al., 2015; Fang et al., 2016).
Alternatively, EVs can be engineered toward the development
of novel drug delivery systems (DDS). Drug loaded EVs
can be used to transport and deliver therapeutic cargo to
target diseased cells and tissues (Batrakova and Kim, 2015;
Vader et al., 2016). These natural DDS could be an appealing
alternative to the more established synthetic DDS, by avoiding
toxicity and rapid clearance from the organism, as well as
a better membrane matching capacity (Batrakova and Kim,
2015). Dendritic cell-derived EVs were able to deliver siRNA
to the brain in mice, demonstrating their potential use as
targeted therapy for neurological diseases (Alvarez-Erviti et al.,
2011). Macrophage-derived EVs loaded with catalase provided
increased neuroprotective effects in in vitro and in vivo models
of Parkinson’s disease, compared to free catalase (Haney et al.,
2015). Recently, multiple studies have successfully developed
EVs as DDS for cancer therapy (Pascucci et al., 2014; Tian
et al., 2014; Kim et al., 2016, 2018; Kooijmans et al., 2016, 2018;
Jia et al., 2018; Li et al., 2018). Intravenously injected EVs
from dendritic cells delivered doxorubicin specifically to tumor
tissues in mice, leading to the inhibition of tumor growth with
lower toxcicity (Tian et al., 2014). MSC incubated with a high
Paclitaxel concentration secreted EVs loaded with this drug,
successfully inhibiting tumor growth in vitro (Pascucci et al.,
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FIGURE 5 | Comparing MSC-EV production in bioreactor and static culture systems, using MSC from different sources. (A) EV concentration (particles/mL) in the
cell culture conditioned medium from BM, AT, and UCM MSC cultures in static and Vertical-WheelTM bioreactor systems. MSC from three different donors were
used for each tissue source (i.e., n = 3 biological replicates). Results are presented as mean ± SEM (n = 3). Upper-right panel: Summarized paired analysis
comparing EV concentration in static and Vertical-WheelTM bioreactor systems, for each MSC donor. Paired statistical analysis (paired t-test ∗∗P = 0.0027) (n = 9).
(B) Specific EV concentration (particles/cell) in the cell culture conditioned medium from BM, AT, and UCM MSC cultures in static and Vertical-WheelTM bioreactor
systems. MSC from three different donors were used for each tissue source. In static cultures, each T-175 yielded 1.2 – 6.6 × 106 cells upon 4 – 9 days of
expansion, regardless of the cell tissue source. Results are presented as mean ± SEM (n = 3; n = 2 for UCM-static). Upper-right panel: Summarized paired analysis
comparing specific EV concentration in static and Vertical-WheelTM bioreactor systems, for each MSC donor. (C) Particle to protein ratios (PPR) (particle/µg protein)
of EV samples obtained from BM, AT and UCM MSC, cultured in static and Vertical-WheelTM bioreactor systems. MSC from three different donors were used for
each tissue source. Results are presented as mean ± SEM (n = 3). Upper-right panel: Violin plot of PPR of MSC-EV samples obtained in static and Vertical-WheelTM
bioreactor systems.
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TABLE 2 | Fold changes in EV concentration and EV productivity in the cell culture
conditioned medium from the bioreactor system compared to static conditions.
EV concentration fold
change (bioreactor/static)
EV productivity fold change
(bioreactor/static)
BM 4.0 ± 0.6 1.4 ± 0.3
AT 4.4 ± 1.2 3.7 ± 1.0
UCM 8.8 ± 3.8 3.9 ± 1.4
Global 5.7 ± 0.9 3.0 ± 0.5
Results from each of the 3 MSC sources used (BM, AT, and UCM), as well as
global fold change averages from all the sources. Three biological replicates (i.e.,
MSC from three different human donors) were used for each MSC source (n = 3).
For each MSC source, results are presented as the average of fold changes for
each donor, in order to account for biological diversity. Global fold changes are
presented as the average of fold changes from each MSC source. Results are
presented as mean ± SEM.
2014). Additionally, EVs can be further engineered to improve
specificity and retention on target cells and tissues (Jia et al., 2018;
Kooijmans et al., 2016, 2018).
Despite the promising potential of EVs for therapeutic
applications, large EV doses are expected to be required to
achieve therapeutic effects in clinical settings. This requires
the development of robust manufacturing processes that could
increase the consistency and scalability of EV production, which
are currently lacking.
The present work aimed to establish a scalable culture
platform for the manufacturing of MSC-EVs in S/XF culture
conditions. This was achieved by building on previous work
from our group where a S/XF microcarrier-based culture
system was implemented in single-use bioreactors (VWBR),
employing a hPL culture supplement (UltraGROTM-PURE) for
MSC expansion (de Sousa Pinto et al., 2019). In the present study,
EVs were produced by MSC isolated from 3 different human
tissue sources (BM, AT and UCM) in a process that comprises
a cell expansion stage and a culture medium conditioning stage.
S/XF culture conditions were implemented by exclusively
applying products without any animal components, namely hPL
as a culture supplement used in the cell expansion stage, instead
of the more commonly used FBS, as well as animal product-free
plastic microcarriers and TrypLE as a cell detaching solution.
Multiple studies have revealed hPL-supplemented media to be
efficient for the isolation and expansion of MSC from various
origins (Doucet et al., 2005; Kinzebach et al., 2013; Reinisch
et al., 2015), cultured both in static and dynamic systems (de
Soure et al., 2017; de Sousa Pinto et al., 2019), as well as for the
expansion of other cell types (Naveau et al., 2010; Mazzocca et al.,
2012; Hofbauer et al., 2014; Hildner et al., 2015). However, the
fact that hPL products originate from human donors presents
some constraints, such as the risk of transmission of human
diseases by viruses, ill-definition and the possibility of triggering
immune responses (Hemeda et al., 2014). The ideal option for
production of clinical-grade cell based therapies would be a
chemically defined, animal component-free medium (including
human). However, there are very few of these options available,
namely for MSC culture. Therefore, presently, hPL seems to
be the most promising and cost-effective alternative to FBS
supplementation in cell culture medium for now, being more
readily translatable to a clinical setting, especially considering
that gamma irradiated hPL products allowing significant viral
reduction have already been developed (Huang et al., 2019).
Culture medium supplements such as FBS and hPL have
a large amount of protein and vesicle contents, presenting
an additional challenge for their use in EV manufacturing.
These components are prone to be co-isolated with the EV
fraction, thus contaminating the end product (Witwer et al.,
2019). For this reason, we removed hPL at the end of the
MSC expansion period and hPL-free medium was used for the
medium conditioning period. MSC were cultured for 48 h in
this supplement-free medium, which could be a stress factor
for cell culture. However, we did not observe any significant
reduction in cell number, cell viability or microcarrier occupancy
during this stage. Furthermore, LDH activity did not change
significantly over this period for any of the MSC sources.
Therefore, there were no indications that MSC were experiencing
significant stress in culture, due to the absence of hPL in the 48 h
conditioning period. Still, MSC might potentially undergo some
alterations over this period. Minimal identity criteria commonly
used to define multipotent MSC could suffer modifications,
namely their in vitro multilineage differentiation capacity or their
immunophenotype (i.e., expressing CD73, CD90, and CD105,
lacking the expression of hematopoietic and endothelial markers
CD11b, CD14, CD19, CD34, CD45, CD79a and HLA-DR)
(Viswanathan et al., 2019). Of notice, MSC expanded in the
VWBR system maintain the typical MSC immunophenotype, as
previously reported by our group (de Sousa Pinto et al., 2019).
Further work could be performed by comparing the MSC features
before and after the culture medium conditioning period.
Bioreactor systems such as VWBR present several advantages
for the manufacturing of cell-based therapies. Cell culture
on microcarriers in suspension inside a bioreactor allows an
increase of available surface area per volume ratio, enabling
higher cell concentrations in culture. Bioreactors also allow
the implementation of culture monitoring and control systems,
providing an additional advantage to optimize culture conditions,
by adjusting feeding regimes and physicochemical parameters
(e.g., O2 concentration and pH) according to real-time
culture measurements.
In this work, we established a bioreactor process in 100 mL
VWBR vessels. This process can be scaled-up to VWBR with
a working volume of 3 L or higher (up to 500 L), which
include an integrated control system, allowing for a controlled
manufacturing process. To the best of our knowledge, this study
is the first to establish a S/XF microcarrier-based culture system in
bioreactors for the manufacturing of MSC-EVs, using MSC from
3 different human tissue sources (BM, AT and UCM). It is also the
first to implement the VWBR configuration for EV production.
Cell expansion in this bioreactor culture system allowed an
increase in EV concentration in the conditioned medium when
compared to traditional static systems (5.7 ± 0.9 global fold
increase), partly due to higher cell concentrations obtained
in VWBR. However, in addition to that, the EV productivity
(i.e., specific EV concentration) also increased in bioreactors
(3.0 ± 0.5 global fold increase), meaning that each cell secreted
more EVs when MSC were cultured in the VWBR, compared to
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static conditions. Although this difference was not found to be
statistically significant, this was likely due to the heterogeneities
between different tissue sources and donors. For example, if
we had not considered the results from one of the BM MSC
donors (for which EV productivity decreased in the bioreactor,
contradicting the observed general tendency of our study), this
difference would be statistically significant. This reinforces the
relevance of testing MSC from multiple tissue donors in order
to account for intrinsic biological variability. Of notice, this
study was performed using MSC from 3 different donors for
each tissue source, comprising a total 9 random human donors.
Still, further work may be performed with additional donors in
order to more thoroughly account for donor variability and its
impact. Altogether, the higher EV concentrations achieved in
VWBR were due to higher cell densities, as well as to higher EV
productivities by MSC.
Overall, in the conditions of our study, UCM MSC allowed the
highest EV concentration and EV productivity in the bioreactor
system. They also showed the highest fold increase in both
parameters when compared to static systems. Therefore, UCM
seems to be the MSC source that benefits the most from
cultivation in the VWBR system, being the most promising of
the three tissue sources studied for scalable MSC-EV production.
This is in line with previous work where UCM MSC have been
described to allow higher EV productivity than BM and AT MSC
in static culture (Haraszti et al., 2018).
Nonetheless, the real applicability of these MSC-EVs depends
on their biological function. Given their different tissue origins,
we can expect that EVs obtained from cells derived from each
MSC source will have different functional characteristics. Indeed,
different intrinsic therapeutic features have been described for
MSC derived from different tissues (Ribeiro et al., 2013). In
order to develop therapeutic products, based on the MSC-EVs
manufactured in this work, additional functional studies will be
required. These could include, for example, (i) scratch assays
or tube formation assays using endothelial cells to determine
the ability of MSC-EVs to promote angiogenesis in the context
of vascular repair (Vrijsen et al., 2016) or (ii) cell uptake
assays to determine EV uptake by target cancer cells, to assess
their potential as drug delivery vehicles for cancer therapy
(Kooijmans et al., 2018).
The increase observed in EV productivity in VWBR can
be explained by multiple reasons. EV secretion by MSC may
have been stimulated by fluid flow, promoted by the VWBR
mixing system. Fluid flow has already been described to
stimulate EV secretion in osteocytes through a Ca2+-mediated
response (Morrell et al., 2018). Additionally, when MSC were
cultured in the bioreactor system, cells attached to the surface
of plastic microcarriers and proliferated. Later in culture,
microcarrier aggregates were formed and, consequently, MSC
formed aggregates as well, as previously observed (Frauenschuh
et al., 2007; Eibes et al., 2010). MSC culture in spheroids
has been described to lead to higher secretion of paracrine
factors (Bhang et al., 2011; Costa et al., 2017), as well as
to an increased secretion of microvesicles (Cha et al., 2018).
Hence, aggregate formation could be leading to an increased
EV secretion in the VWBR system. Finally, MSC cultured
in the VWBR system are likely to be exposed to lower
oxygen concentrations than in static platforms. The VWBR
agitation system allows mixing of the cell culture medium,
achieving a homogeneous oxygen concentration. However,
there is no aeration system in the 100 mL VWBR, so
oxygen exchange occurs only at the surface gas-liquid interface.
Considering the differences between the geometries of the
VWBR vessel and the T-flask, oxygen concentration would be
expectedly lower in the VWBR system than in static. This
could potentially be a contributing factor for the observed
increase in EV secretion when cells were expanded in the
bioreactor system. Previous studies have demonstrated an
increase in EV secretion when different cell types (including
MSC) were cultured under hypoxic conditions (ranging from 0.1
to 3% O2, compared to controls) (King et al., 2012; Salomon
et al., 2013; Panigrahi et al., 2018). Although all of these
factors might lead to an increased EV productivity in the
VWBR, additional studies would be needed to determine their
actual contributions.
Zeta potential measurements revealed that the surface charge
of obtained MSC-EVs were generally similar, regardless the
production platform and MSC source used, ranging between
−15.5 ± 1.6 mV and −19.4 ± 1.4 mV. These surface
charges are moderately negative, as it was expected considering
that EVs are cell-derived nanoparticles, therefore containing
negatively charged phospholipids. The values of zeta potential
obtained herein were in line with other studies reporting zeta
potential measurements for EVs derived from cell culture (Akagi
et al., 2014; Hood et al., 2014; Kesimer and Gupta, 2015;
Rupert et al., 2017).
Further EV characterization revealed that bioreactors
improved not only EV quantity but also their purity, as assessed
by Western blot and PPR. Western blot analysis revealed that
synthenin, CD63 and CD81 (key proteins involved in EV
biogenesis and commonly used as protein markers) were in
general more abundant in EVs obtained from bioreactors than
from their static counterparts (Figure 3Bii). Therefore, EVs
from bioreactors seem to have a higher purity than EVs obtained
from static system, since a higher amount of synthenin, CD63
and CD81 were detected for the same amount of total protein.
This observation corroborates the increased EV concentration in
VWBR identified by NTA. The fact that bioreactor EV samples
showed increased levels of EV protein markers validates the
hypothesis that the increased concentration of particles detected
by NTA corresponds to an increased concentration of EVs and
not of protein aggregates.
EV purity was also assessed by estimating the PPR for
each EV sample (Webber and Clayton, 2013). PPR was more
homogeneous and reproducible in EV samples obtained from
bioreactors compared to those produced under static conditions
and the median PPR was higher in the bioreactor system
(Figure 5C). A more homogeneous environment in VWBR
offers a more reproducible process for different sources and
donors. Constant agitation provides the cells with a more
homogeneous access to nutrients, thus allowing a more robust
MSC-EV manufacturing process. Therefore, the bioreactor
platform established in this work is expected to allow the
robust production of MSC-EVs at higher purities, compared
to static systems.
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In our previous work focused on the establishment of a
S/XF microcarrier-based culture system in single-use bioreactors
(VWBR) (de Sousa Pinto et al., 2019), an economic evaluation
revealed that the application of this culture system allowed
a cost reduction for MSC manufacturing when compared to
static cell culture using T-flasks. Therefore, it can be expected
that the application of this bioreactor system will also allow a
cost reduction for the production of MSC-EVs, compared to
static platforms.
A few manufacturing processes for the production of
EVs have been previously studied. The Integra CELLine
culture system is a static platform that has been used to
optimize EV production (Mitchell et al., 2008). This is a two-
compartment culture flask with a semi-permeable membrane
separating a cell-containing compartment from a larger medium
compartment. When mesothelioma and NK cells were cultured
in this system, a 12-fold and a 8-fold increase in EV
(protein) concentration was observed, respectively, compared
to traditional T-flasks (Mitchell et al., 2008). This system
also allowed a 13- to 16-fold increase in EV (protein)
concentration from bladder carcinoma cells (Jeppesen et al.,
2014). The CELLine system allows culture medium change while
EVs are retained in the cell compartment, enabling higher
EV concentrations. However, this static system has limited
scalability, thus not being the most suitable option for large-
scale EV production.
Watson and colleagues developed a hollow-fiber bioreactor
platform for the production of HEK-derived EVs (Watson
et al., 2016). The authors reported a 10-fold increase in EV
concentration compared with static culture, which was sustained
by an increased purity (both increased PPR and protein marker
expression). However, EV size distribution profiles were more
dispersed in the bioreactors, which is the opposite from what
we observed in our study with the VWBR system. Mendt and
colleagues manufactured BM MSC-derived EVs in a closed
system, hollow-fiber bioreactor, named Quantum (Mendt et al.,
2018). They were able to achieve 1.04 × 1010 particles/mL
on average, which was higher, but comparable with the EV
concentrations we obtained in the VWBR system (5.5± 0.8× 109
particles/mL) herein.
Hollow-fiber bioreactors (i.e., without mechanical agitation)
provide surface immobilization of cells on the fibrous material
and represent a suitable configuration to obtain an increased
EV concentration in culture, since culture medium can
be recirculated while EVs are retained by the hollow-fiber
membranes. However, stirred bioreactors as the VWBR may
allow a better fine-tuning of EV production by manipulating
process parameters. For example, agitation may play an
important role in EV secretion, since fluid flow seems
to have impact on this process. Further studies may be
developed in the VWBR, testing the impact of agitation on
EV production. Other process parameters, such as oxygen
concentration, temperature and pH, are also likely to play
a role in EV secretion by cultured MSC and are more
easily controlled in a VWBR, especially when integrated
with a control system. Further studies addressing the impact
of these parameters on EV production using the VWBR
system would be relevant to fine-tune and optimize MSC-
EV production.
CONCLUSION
In this study, we have successfully developed a scalable S/XF
microcarrier-based bioreactor culture system for the robust
production of MSC-EVs, using MSC from 3 different human
tissue sources (BM, AT, and UCM). This system allowed
the production of MSC-EVs at higher concentration and
productivity when compared to traditional static culture systems.
It also allowed to obtain a more robust MSC-EV manufacturing
process, regarding their purity. Further developments of this
system will need to take into consideration a proper balance
between EV production and function. Additional studies will be
required to characterize the therapeutic potential of these MSC-
EVs. The MSC-EVs obtained through this scalable platform are
promising for the development of multiple therapeutic products
and DDS, targeting a variety of diseases.
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